Guidelines prostate brachytherapy
Tumour and target volumes in permanent prostate brachytherapy: A supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy

https://doi.org/10.1016/j.radonc.2007.01.014Get rights and content

Abstract

The aim of this paper is to supplement the GEC/ESTRO/EAU recommendations for permanent seed implantations in prostate cancer to develop consistency in target and volume definition for permanent seed prostate brachytherapy.

Recommendations on target and organ at risk (OAR) definitions and dosimetry parameters to be reported on post implant planning are given.

Section snippets

ICRU definitions [35]

Gross tumour volume (GTV). The gross tumour volume corresponds to the gross palpable, visible or clinically demonstrable location and extent of the malignant growth.

Given the TNM definition for prostate cancer, GTV can only be defined for tumour stages larger than T1c. For these tumour stages (>T1c), the GTV definition can be useful, certainly in cases where the tumour area can be identified, not only by digital rectal examination, but also by radiological examinations including transrectal

Conclusions

These recommendations should be considered in conjunction with the ESTRO/EAU/EORTC recommendations on permanent seed implantation for localised prostate cancer which were published in 2000. This guidance was, as noted in the paper, intended for those embarking on brachytherapy to identify the factors related to successful outcome but did not focus on target (prostate gland) or organ at risk (prostatic urethra, rectum) contouring, target definition, dosimetric parameters regarding target

References (87)

  • J.M. Crook et al.

    Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk

    Brachytherapy

    (2005)
  • M. Debois et al.

    The contribution of magnetic resonance imaging to the three-dimensional treatment planning of localized prostate cancer

    Int J Radiat Oncol Biol Phys

    (1999)
  • D.F. Dubois et al.

    Source localization following permanent transperineal prostate interstitial brachytherapy using magnetic resonance imaging

    Int J Radiat Oncol Biol Phys

    (1997)
  • J.S. Eshleman et al.

    Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: Extraprostatic seed placement correlates with migration

    Int J Radiat Oncol Biol Phys

    (2004)
  • L. Gong et al.

    Ultrasonography and fluoroscopic fusion for prostate brachytherapy dosimetry

    Int J Radiat Oncol Biol Phys

    (2002)
  • C. Haie-Meder et al.

    Recommendations from Gynaecological (GYN GEC-ESTRIO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GRV and CTV

    Radiother Oncol

    (2005)
  • K. Haustermans et al.

    Cell kinetic measurements in prostate cancer

    Int J Radiat Oncol Biol Phys

    (1997)
  • A. Haworth et al.

    Impact of selection of post-implant technique on dosimetry parameters for permanent prostate implants

    Brachytherapy

    (2005)
  • E.M. Horwitz et al.

    Impact of target volume coverage with Radiation Therapy Oncology Group (RTOG) 98-05 guidelines for transrectal ultrasound guided permanent Iodine-125 prostate implants

    Radiother Oncol

    (2003)
  • G. Kovacs et al.

    GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer

    Radiother Oncol

    (2005)
  • C.A. Kunos et al.

    Migration of implanted free radioactive seeds for adenocarcinoma of the prostate using a Mick applicator

    Brachytherapy

    (2004)
  • W.R. Lee et al.

    Postimplant analysis of transperineal intestitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution

    Int J Radiat Oncol Biol Phys

    (2000)
  • W.R. Lee et al.

    Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy

    Int J Radiat Oncol Biol Phys

    (2002)
  • P. Mangili et al.

    Comparative study of permanent interstitial prostate brachytherapy post-implant evaluation among seven Italian institutes

    Radiother Oncol

    (2004)
  • P.W. McLaughlin et al.

    Comparison of MRI pulse sequences in defining prostate volume after permanent implantation

    Int J Radiat Oncol Biol Phys

    (2002)
  • G.S. Merrick et al.

    Seed fixicity in the prostate/periprostatic region following brachytherapy

    Int J Radiat Oncol Biol Phys

    (2000)
  • G.S. Merrick et al.

    Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland

    J Urol

    (2003)
  • M.A. Moerland et al.

    Evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging

    Int J Radiat Oncol Biol Phys

    (1997)
  • S. Nag et al.

    The American Brachytherapy Society recommendations for permanent prostate brachytherapy post-implant dosimetric analysis

    Int J Radiat Oncol Biol Phys

    (2000)
  • S. Nag et al.

    American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer

    Int J Radiat Oncol Biol Phys

    (1999)
  • V. Narayana et al.

    Impact of differences in ultrasound and computed tomography volumes on treatment planning of permanent prostate implants

    Int J Radiat Oncol Biol Phys

    (1997)
  • J.E. Oesterling et al.

    Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathologic stage in 275 patients with clinically localized adenocarcinoma of the prostate

    J Urol

    (1987)
  • R.A. Older et al.

    Radioactive implant migration in patients treated for localized prostate cancer with interstitial brachytherapy

    J Urol

    (2001)
  • R. Ove et al.

    Standardization of prostate brachytherapy treatment plans

    Int J Radiat Oncol Biol Phys

    (2001)
  • A.W. Partin et al.

    Prostate specific antigen in the staging of localised prostate cancer: influence of tumour differentiation, tumour volume and benign hyperplasia

    J Urol

    (1990)
  • A.W. Partin et al.

    Morphometric measurements of tumor volume and per cent of gland involvement as predictor of pathological stage in clinical stage B prostate cancer

    J Urol

    (1989)
  • A. Polo et al.

    MR and CT image fusion for postimplant analysis in permanent prostate seed implants

    Int J Radiat Oncol Biol Phys

    (2004)
  • R. Pötter et al.

    Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image based treatment planning in cervix cancer brachytherapy – 3D dose volume parameters and aspects of 3D image-based anatomy, radiations physics, radiobiology

    Radiother Oncol

    (2006)
  • L. Potters et al.

    Towards a dynamic real-time intraoperative permanent prostate brachytherapy methodology

    Brachytherapy

    (2003)
  • L. Potters et al.

    A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy

    Int J Radiat Oncol Biol Phys

    (2001)
  • L. Potters et al.

    Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation

    Radiother Oncol

    (2004)
  • F.A. Siebert et al.

    The design and testing of a solid phantom for the verification of a commercial 3D seed reconstruction algorithm

    Radiother Oncol

    (2005)
  • H. Sommerkamp et al.

    Seed loss in interstitial radiotherapy of prostatic carcinoma with 125I

    Int J Radiat Oncol Biol Phys

    (1988)
  • Cited by (243)

    • Best practice in brachytherapy

      2022, Cancer/Radiotherapie
      Citation Excerpt :

      Brachytherapy allows a heterogeneous dose distribution into the CTV according to increase the dose in the tumour index or specific area at high risk of local recurrence. The Groupe européen de curiethérapie of the European Society for Therapeutic Radiology and Oncology (Gec-ESTRO) have published recommendations for target volume definition and dose levels to consider according to the tumour location [7–12]. Organs at risk are healthy tissues located around or inside the CTV whose radiosensitivity can affect dose prescription or planning.

    • Prostate cancer brachytherapy: SFRO guidelines 2021

      2022, Cancer/Radiotherapie
      Citation Excerpt :

      To facilitate registration, it is useful to first demarcate the prostate volumes in the two series of images and then fuse the images of the two structures. Clinical target volume (CTV) corresponds to the entire prostate gland with a possible 3-mm expansion excluding the rectum and neck of the bladder [5,71]. The planning target volume (PTV) corresponds to the CTV [71].

    View all citing articles on Scopus
    View full text